{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:18:32Z","timestamp":1783048712260,"version":"3.54.6"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Here, we present the first reported case of a child presenting with unprovoked deep vein thrombosis (DVT) due to the unique combination of May\u2013Thurner syndrome, protein S deficiency and lupus anticoagulant. Of interest to the clinician and scientific reader alike is that this one-of-a-kind interplay between mechanical obstruction and hypercoagulability caused a very extensive blood clot which extended from the left popliteal to the femoral and iliac veins. A 12-month course of warfarin with a target INR value of 2.5 was used to treat the DVT which would be of use to note for any future clinicians treating children presenting with extensive DVTs and multiple pro-thrombotic risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 14-year-old Asian (Han Chinese) boy presented to the children\u2019s assessment unit with a 4-day history of left-sided groin pain radiating to the left knee. On examination his left thigh was swollen. Initial blood tests showed no clotting abnormalities and a normal platelet count. An ultrasound doppler of the lower limb veins was performed which showed an extensive thrombus involving the left popliteal, femoral, and iliac veins. An MRI of the abdomen and pelvis demonstrated that the left common iliac vein was narrowed by the left common iliac artery thereby confirming May\u2013Thurner syndrome. He was started on enoxaparin bridging therapy to rivaroxaban initially. Further blood tests were positive for lupus anticoagulant. He was also found to be protein S deficient. After further discussions with haematological services a 12-month course of warfarin was indicated due to rivaroxaban being contraindicated in patients with antiphospholipid syndrome (APS). Our patient was suspected of having APS but to confirm, a second blood test had to be sent at least 12\u00a0weeks after the first. Warfarin was therefore started as we could not wait 12\u00a0weeks to confirm or refute a diagnosis of APS. The patient eventually tested negative for APS. After 12\u00a0months of treatment with warfarin, a repeat ultrasound doppler was performed which showed that the thrombus had almost entirely resolved with good flow in all the previously affected veins. He was subsequently started on a lower dose of rivaroxaban as maintenance therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on our literature search this is the first patient to be reported as having this unique combination of May\u2013Thurner syndrome, protein S deficiency and testing positive for lupus anticoagulant. This case demonstrated that despite the child having such an extensive thrombus and presenting with multiple risk factors for thrombosis, that a 12-month course of warfarin with a target INR of 2.5 was sufficient in resolving his symptoms and facilitated the dissolution of the clot. This case also demonstrated the importance of considering APS as a risk factor for his clot as having this condition would contraindicate the use of DOACs. Testing negative for lupus anticoagulant on his repeat blood test, a reduced dose course of rivaroxaban (at 10\u00a0mg instead of 20\u00a0mg once daily) was indicated and was successful in ensuring that there was no recurrence of DVT with no reports of major or minor bleeds nor of any thromboembolic events occurring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-026-06028-5","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:46:07Z","timestamp":1778499967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deep vein thrombosis in a 14-year-old boy with a combination of May\u2013Thurner syndrome, protein S deficiency and lupus anticoagulant: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Vladislav","family":"Makeev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Zeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"5","key":"6028_CR1","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.21037\/cdt.2020.03.07","volume":"11","author":"S Poyyamoli","year":"2021","unstructured":"Poyyamoli S, Mehta P, Cherian M, Anand RR, Patil SB, Kalva S, et al. May\u2013Thurner syndrome. Cardiovasc Diagn Ther. 2021;11(5):1104\u201311.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"7","key":"6028_CR2","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.avsg.2013.05.001","volume":"27","author":"AY Mousa","year":"2013","unstructured":"Mousa AY, AbuRahma AF. May\u2013Thurner syndrome: update and review. Ann Vasc Surg. 2013;27(7):984\u201395.","journal-title":"Ann Vasc Surg"},{"issue":"3","key":"6028_CR3","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1055\/s-0040-1714694","volume":"4","author":"DM Warad","year":"2020","unstructured":"Warad DM, Rao AN, Bjarnason H, Rodriguez V. Clinical outcomes of May\u2013Thurner syndrome in pediatric patients: a single institutional experience. TH Open. 2020;4(3):e189\u201396.","journal-title":"TH Open"},{"issue":"5","key":"6028_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/MOH.0000000000000663","volume":"28","author":"R Majumder","year":"2021","unstructured":"Majumder R, Nguyen T. Protein S: function, regulation, and clinical perspectives. Curr Opin Hematol. 2021;28(5):339\u201344.","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"6028_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1160\/TH14-06-0533","volume":"113","author":"UC Klostermeier","year":"2015","unstructured":"Klostermeier UC, Limperger V, Kenet G, Kurnik K, Gelas MA, Finckh U, et al. Role of protein S deficiency in children with venous thromboembolism. An observational international cohort study. Thromb Haemost. 2015;113(2):426\u201333.","journal-title":"Thromb Haemost"},{"key":"6028_CR6","volume-title":"Antiphospholipid syndromes","author":"JG Bustamante","year":"2024","unstructured":"Bustamante JG, Goyal A, Rout P, Singhal M. Antiphospholipid syndromes. Treasure Island: StatePearls; 2024."},{"issue":"3","key":"6028_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/BF01960918","volume":"3","author":"R Virchow","year":"1851","unstructured":"Virchow R. Ueber die Erweiterung kleinerer Gef\u00e4fse\u2014Hierzu Tab. IV. Arch Pathol Anat Physiol Klin Med. 1851;3(3):427\u201362. https:\/\/doi.org\/10.1007\/BF01960918.","journal-title":"Arch Pathol Anat Physiol Klin Med"},{"issue":"5","key":"6028_CR8","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/jth.15284","volume":"19","author":"L Avila","year":"2021","unstructured":"Avila L, Cullinan N, White M, Gaballah M, Cahill AM, Warad D, et al. Pediatric May\u2013Thurner syndrome-systematic review and individual patient data meta-analysis. J Thromb Haemost. 2021;19(5):1283\u201393.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"6028_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.7326\/0003-4819-106-5-677","volume":"106","author":"L Engesser","year":"1987","unstructured":"Engesser L, Broekmans AW, Bri\u00ebt E, Brommer EJ, Bertina RM. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med. 1987;106(5):677\u201382.","journal-title":"Ann Intern Med"},{"key":"6028_CR10","volume-title":"Protein S deficiency","author":"A Gupta","year":"2022","unstructured":"Gupta A, Tun AM, Gupta K, Tuma F. Protein S deficiency. Treasure Island: StatPearls; 2022."},{"key":"6028_CR11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1365-2141.2010.08543.x","volume":"154","author":"TT Biss","year":"2011","unstructured":"Biss TT, Chalmers EA. Addendum to British Society for Haematology guideline on the investigation, management and prevention of venous thrombosis in children. Br J Haematol. 2011;154:196\u2013207.","journal-title":"Br J Haematol"},{"issue":"1","key":"6028_CR12","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","volume":"7","author":"C Male","year":"2020","unstructured":"Male C, Lensing AWA, Palumbo JS, Kumar R, Nurmeev I, Hege K, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020;7(1):e18-27.","journal-title":"Lancet Haematol"},{"issue":"1","key":"6028_CR13","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","volume":"8","author":"J Halton","year":"2021","unstructured":"Halton J, Brand\u00e3o LR, Luciani M, Bomgaars L, Chalmers E, Mitchell LG, et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial. Lancet Haematol. 2021;8(1):e22-33.","journal-title":"Lancet Haematol"},{"issue":"2","key":"6028_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/jth.15158","volume":"19","author":"V Pengo","year":"2021","unstructured":"Pengo V, Hoxha A, Andreoli L, Tincani A, Silvestri E, Prisco D, et al. Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): two-year outcomes after the study closure. J Thromb Haemost. 2021;19(2):531\u20135.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"6028_CR15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.7326\/M19-0291","volume":"171","author":"J Ordi-Ros","year":"2019","unstructured":"Ordi-Ros J, S\u00e1ez-Comet L, P\u00e9rez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salom\u00f3 A, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med. 2019;171(10):685\u201394.","journal-title":"Ann Intern Med"},{"key":"6028_CR16","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1055\/a-0959-6230","volume":"191","author":"T Heller","year":"2019","unstructured":"Heller T, Teichert C, Hafer J, Weber MA, Kr\u00f6ger JC, Meinel FG. Prevalence of May\u2013Thurner syndrome in patients with deep vein thrombosis at a large medical referral center pr\u00e4valenz des May\u2013Thurner\u2014Syndroms bei Patienten mit iliofemoraler tiefer Venenthrombose an einem universit\u00e4ren Zentrum. Fortschr R\u00f6ntgenstr. 2019;191:1107\u201317.","journal-title":"Fortschr R\u00f6ntgenstr"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06028-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:01:08Z","timestamp":1783047668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06028-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6028"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06028-5","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required for this single case report, in accordance with the national policy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"366"}}